| Literature DB >> 25878712 |
Yibo Feng1, Xiaojuan Zhao2, Fang Lv2, Jinqiu Zhang2, Bihua Deng2, Yanhong Zhao2, Yuanliang Hu1, Deyun Wang1, Jiaguo Liu1, Yu Lu2, Ruonan Bo1, Zhenguang Liu1.
Abstract
The aim of this study was to optimize the preparation conditions of salidroside liposome with high encapsulation efficiency (EE) and to study the immunological enhancement activity of salidroside liposome as porcine circovirus type 2 virus (PCV-2) vaccine adjuvant. Response surface methodology (RSM) was selected to optimize the conditions for the preparation of salidroside liposome using Design-Expert V8.0.6 software. Three kinds of salidroside liposome adjuvants were prepared to study their adjuvant activity. BALB/c mice were immunized with PCV-2 encapsulated in different kinds of salidroside liposome adjuvants. The PCV-2-specific IgG in immunized mice serum was determined with ELISA. The results showed that when the concentration of ammonium sulfate was 0.26 mol·L(-1), ethanol volume 6.5 mL, temperature 43°C, ethanol injection rate 3 mL·min(-1), and salidroside liposome could be prepared with high encapsulation efficiency of 94.527%. Salidroside liposome as adjuvant could rapidly induce the production of PCV-2-specific IgG and salidroside liposome I adjuvant proved to provide the best effect among the three kinds of salidroside liposome adjuvants.Entities:
Year: 2015 PMID: 25878712 PMCID: PMC4386707 DOI: 10.1155/2015/178128
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Levels and code of variables chosen for Box-Behnken design.
| Factors | Levels and range | ||
|---|---|---|---|
| −1 | 0 | 1 | |
|
| 0.20 | 0.25 | 0.30 |
|
| 4 | 6 | 8 |
|
| 40 | 45 | 50 |
|
| 2 | 3 | 4 |
The design and results of Box-Behnken experiment.
| Number | Levels of independent factors | Response: EE (%) | ||||
|---|---|---|---|---|---|---|
|
|
|
|
| Predicted acquired EE | Practical acquired EE | |
| 1 | 0.30 | 6 | 45 | 4 | 88.50 | 88.36 |
| 2 | 0.30 | 4 | 45 | 3 | 84.10 | 84.38 |
| 3 | 0.25 | 6 | 40 | 2 | 91.20 | 91.18 |
| 4 | 0.25 | 6 | 45 | 3 | 94.70 | 84.55 |
| 5 | 0.20 | 4 | 45 | 3 | 85.70 | 85.92 |
| 6 | 0.25 | 6 | 50 | 2 | 76.80 | 77.27 |
| 7 | 0.25 | 8 | 45 | 4 | 84.90 | 94.60 |
| 8 | 0.20 | 8 | 45 | 3 | 87.30 | 87.65 |
| 9 | 0.25 | 6 | 45 | 3 | 94.10 | 94.60 |
| 10 | 0.30 | 6 | 50 | 3 | 87.90 | 87.65 |
| 11 | 0.30 | 6 | 40 | 3 | 91.30 | 91.69 |
| 12 | 0.25 | 4 | 40 | 3 | 85.10 | 84.63 |
| 13 | 0.30 | 6 | 45 | 2 | 88.20 | 87.93 |
| 14 | 0.20 | 6 | 40 | 3 | 92.20 | 92.17 |
| 15 | 0.20 | 6 | 45 | 2 | 86.00 | 86.21 |
| 16 | 0.25 | 6 | 45 | 3 | 94.60 | 94.60 |
| 17 | 0.20 | 6 | 50 | 3 | 85.40 | 84.47 |
| 18 | 0.25 | 8 | 45 | 2 | 85.60 | 85.12 |
| 19 | 0.25 | 4 | 45 | 2 | 79.50 | 79.57 |
| 20 | 0.25 | 8 | 40 | 3 | 89.40 | 89.78 |
| 21 | 0.25 | 8 | 50 | 3 | 82.40 | 82.95 |
| 22 | 0.30 | 8 | 45 | 3 | 91.20 | 91.20 |
| 23 | 0.25 | 4 | 45 | 4 | 81.80 | 82.00 |
| 24 | 0.20 | 6 | 45 | 4 | 87.30 | 87.22 |
| 25 | 0.25 | 4 | 50 | 3 | 80.30 | 80.00 |
| 26 | 0.25 | 6 | 40 | 4 | 84.20 | 83.93 |
| 27 | 0.25 | 6 | 50 | 4 | 86.20 | 86.40 |
| 28 | 0.25 | 6 | 45 | 3 | 94.50 | 94.60 |
| 29 | 0.25 | 6 | 45 | 3 | 95.10 | 94.60 |
ANOVA for response surface quadratic model.
| Source | Sum of squares | df | Mean Square |
|
| Significance |
|---|---|---|---|---|---|---|
| Model | 657.64 | 14 | 657.64 | 216.15 | <0.0001 | Sig*** |
|
| 4.44 | 1 | 4.44 | 20.43 | 0.0005 | ∗∗ |
|
| 49.21 | 1 | 49.21 | 226.43 | <0.0001 | ∗∗∗ |
|
| 98.61 | 1 | 98.61 | 453.27 | <0.0001 | ∗∗∗ |
|
| 2.61 | 1 | 2.61 | 12.03 | 0.0038 | ∗∗ |
|
| 7.56 | 1 | 7.56 | 34.80 | <0.0001 | ∗∗∗ |
|
| 2.89 | 1 | 2.89 | 13.30 | 0.0026 | ∗∗ |
|
| 0.25 | 1 | 0.25 | 1.15 | 0.3016 | |
|
| 1.21 | 1 | 1.21 | 5.57 | 0.0333 | ∗ |
|
| 2.25 | 1 | 2.25 | 10.35 | 0.0062 | ∗∗ |
|
| 67.24 | 1 | 67.24 | 309.40 | <0.0001 | ∗∗∗ |
|
| 11.82 | 1 | 11.82 | 54.40 | <0.0001 | ∗∗∗ |
|
| 239.39 | 1 | 239.39 | 1101.54 | <0.0001 | ∗∗∗ |
|
| 113.74 | 1 | 113.74 | 523.38 | <0.0001 | ∗∗∗ |
|
| 211.67 | 1 | 211.67 | 974.00 | <0.0001 | ∗∗∗ |
| Residual | 3.04 | 14 | 0.22 | |||
| Lack of fit | 2.52 | 10 | 0.25 | 1.94 | 0.2735 | Not sig. |
| Pure error | 0.52 | 4 | 0.13 | |||
| Cor. total | 660.68 | 28 | ||||
|
| ||||||
* P < 0.05; ** P < 0.01; *** P < 0.001.
Figure 1Response surface (3D) and contour plots showing the interaction of different factors on the response Y. (a) The interaction of ammonium sulfate concentration and ethanol injection volume, (b) the interaction of ammonium sulfate concentration and temperature, (c) the interaction of ammonium sulfate concentration and ethanol injection rate, (d) the interaction of ethanol injection volume and temperature, (e) the interaction of ethanol injection volume and ethanol injection rate, and (f) the interaction of temperature and ethanol injection rate.
The results of EE of salidroside liposome PCV-2.
| Liposome | The volume ratio | EE | TCID50 in liposome/0.2 mL | Total TCID50/0.2 mL |
|---|---|---|---|---|
| Salidroside liposome I PCV-2 | 2 : 1 | 10% | 2.1 × 105 | 2.1 × 106 |
| 3 : 1 | 30% | 4.7 × 105 | 1.6 × 106 | |
| 4 : 1 | 40% | 5.1 × 105 | 1.3 × 106 | |
| 5 : 1 | 60% | 6.3 × 105 | 1.1 × 106 | |
| 6 : 1 | 55% | 5.0 × 105 | 9.0 × 105 | |
|
| ||||
| Salidroside liposome II PCV-2 | 2 : 1 | 8% | 3.3 × 105 | 4.2 × 106 |
| 3 : 1 | 22% | 6.9 × 105 | 3.2 × 106 | |
| 4 : 1 | 44% | 7.0 × 105 | 1.6 × 106 | |
| 5 : 1 | 80% | 8.4 × 105 | 1.1 × 106 | |
| 6 : 1 | 76% | 6.9 × 105 | 9.0 × 105 | |
|
| ||||
| Salidroside liposome III PCV-2 | 2 : 1 | 10% | 4.2 × 105 | 4.2 × 106 |
| 3 : 1 | 30% | 9.5 × 105 | 3.2 × 106 | |
| 4 : 1 | 50% | 7.9 × 105 | 1.6 × 106 | |
| 5 : 1 | 75% | 7.9 × 105 | 1.1 × 106 | |
| 6 : 1 | 70% | 6.3 × 105 | 9.0 × 105 | |
The characteristics of three kinds of liposomes.
| Liposome | Phospholipids | Salidroside | PCV-2 | EE | Size (nm) |
|---|---|---|---|---|---|
| (mg/mL) | (mg/mL) | (TCID50/0.2 mL) | |||
| Salidroside liposome I PCV-2 | 30 | 0.5 | 1.1 × 106 | 60% | 138 ± 22 |
| Salidroside liposome II PCV-2 | 60 | 0.5 | 1.1 × 106 | 80% | 165 ± 18 |
| Salidroside liposome III PCV-2 | 90 | 0.5 | 1.1 × 106 | 75% | 157 ± 12 |
Figure 2Transmission electron micrograph of salidroside liposome PCV-2.
Figure 3In vitro release profile of salidroside liposome PCV-2.
Figure 4The PCV-2-specific IgG level of different groups after vaccination.